3.14
+0.03(+0.96%)
Currency In USD
| Previous Close | 3.11 |
| Open | 3.11 |
| Day High | 3.15 |
| Day Low | 3.05 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.52 |
| Volume | 8,479 |
| Average Volume | 90,914 |
| Market Cap | 81.89M |
| PE | 8.72 |
| EPS | 0.36 |
| Moving Average 50 Days | 3.41 |
| Moving Average 200 Days | 3.36 |
| Change | 0.03 |
If you invested $1000 in Senti Biosciences, Inc. (SNTI) since IPO date, it would be worth $31.46 as of May 31, 2025 at a share price of $3.14. Whereas If you bought $1000 worth of Senti Biosciences, Inc. (SNTI) shares 3 years ago, it would be worth $31.59 as of May 31, 2025 at a share price of $3.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
GlobeNewswire Inc.
May 22, 2025 8:05 PM GMT
Live webcast on Thursday, May 29th at 2:40 PM ETSOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation c
Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202
GlobeNewswire Inc.
May 22, 2025 12:30 PM GMT
SENTI-202 currently being evaluated in Phase 1 study for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemiaSOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: S
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
GlobeNewswire Inc.
May 08, 2025 12:35 PM GMT
Video illustrates SENTI-202’s MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using its novel CD33 OR FLT3 NOT EMCN